Table 3.

Cox regression analyses of the clinical, biological, and FDG PET/CT parameters associated with overall and progression-free survival.

Parameters	PFS		OS
	HR (95%CI)	p	HR (95%CI)	p
Initial MM characteristics
Initial ISS score (1 vs. 2–3)	4.4 (1.3–15.3)	0.019	7.0 (0.9–55.1)	0.066
Initial ISS score (1–2 vs. 3)	4.0 (1.5–10.7)	0.0065	6.6 (1.6–27.8)	0.010
Initial ISS score (1 vs. 2 vs. 3)	2.7 (1.4–5.1)	0.0026	3.8 (1.4–10.6)	0.0098
High-risk cytogenetics	1.2 (0.4–3.7)	0.79	1.0 (0.2–5.2)	0.95
Previous treatments
>2 previous line	1.1 (0.4–2.9)	0.85	1.6 (0.4–6.3)	0.51
Previous ASCT	0.6 (0.2–1.8)	0.41	0.4 (0.7–1.7)	0.21
Biological parameters before anti- CD38 therapy
β2microglobulin ≥ 3.5 mg/	2.8 (0.9–8.5)	0.073	6.0 (0.7–48)	0.089
β2microglobulin > 5.5 mg/L	1.7 (0.6–4.8)	0.31	3.1 (0.8–11.7)	0.098
dFLC	1.0 (0.9–1.0)	0.19	1 (1.0–1.0)	0.013
Abnormal FLC ratio	2.5 (0.7–8.8)	0.15	-	0.95
Albumin ≤ 3.5 g/dL	2.6 (0.9–7.7)	0.082	1.3 (0.3–6.5)	0.72
Hb ≤ 10 g/dL	2.9 (1.1–7.5)	0.030	6.3 (1.6–25)	0.0096
LDH upper than normal	1.1 (0.4–3.1)	0.83	2.1 (0.6–7.9)	0.26
PET parameters before anti-CD38 therapy
Presence of at least one FL	1.4 (0.5–4.1)	0.48	1.8 (0.3–8.5)	0.47
Presence of >3 FLs	4.3 (1.5–12.5)	0.0071	5.2 (1.1–25.4)	0.042
Presence of EMD	2.4 (0.8–7.8)	0.11	2.5 (0.4–14.5)	0.17
Lesion SUVmax > 11.5	2.8 (1.0–7.7)	0.045	3.9 (1.0–14.5)	0.045
Bone marrow ≥ DS 4	1.4 (0.5–4.4)	0.52	2.2 (0.5–8.9)	0.26

dFLC = difference between involved and uninvolved light chains.